|
|
 |
|
Viewing report
|
|
|
|
Tapping Biosimilar Opportunities
MP Advisors, Sep 2011, Pages: 80
Tapping biosimilar opportunities
A Follow on biologic (FOB) or Biosimilar, as commonly known, has been one of the most widely discussed topics in the world of pharma in the last few years. The approaching patent expiry of biologic drugs worth US$ 79 billion during 2010-2015 represents a money-spinning opening for companies with the vital expertise.
The Global Biosimilars industry has witnessed a number of product launches and mergers & acquisitions in the past few years, as a result of the overstrain experienced due to rising healthcare costs, expensive drugs, ageing population and pharma expenditure.
Many biotech industries from India have plunged into the industry to develop biosimilars. They are also strengthening their activities towards developing standards and compendium activities in the fields of cell culture, virology and microbiology while working on chemical medicines as well.
The global development of biosimilars therefore represents a critical part of the future of biotechnology. This report titled 'Tapping biosimilar opportunities' covers the overview, market potential, segmentation and other critical aspects of biosimilars.
This report will also examine significant recent developments in the biosimilars market, especially from an Indian perspective, providing the reader with vital strategic information required to face new opportunities as well as the challenges of the biosimilars revolution. Adding to this would be Japanese firms, who have initiated to take unhurried, but calculated steps contributing to the headway of biosimilars.
|
|
|
|
